Health Care Among Early Leaders In The S&P 500
Upcoming SlideShare
Loading in...5
×
 

Health Care Among Early Leaders In The S&P 500

on

  • 404 views

 

Statistics

Views

Total Views
404
Views on SlideShare
404
Embed Views
0

Actions

Likes
0
Downloads
0
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Health Care Among Early Leaders In The S&P 500 Health Care Among Early Leaders In The S&P 500 Document Transcript

  • Health Care Among Early Leaders In The S&P 500[US Market News] TradingReview360.com: We endeavour to bring you the breaking newsstories from around the globe. The following article is related to the latest US Market News.Read on to learn more:NEW YORK (AP) – Health care stocks have started off the year on a tear.The industry group that includes health care providers, drugmakers and biotechnologycompanies has advanced 7.3 percent this year, making it the second-best in the Standard andPoor’s 500 index, trailing only energy companies. Even drugmakers, traditionally considered asafe-haven play, are outperforming the market.The rally has solid foundations, but not all companies will benefit equally from the influx of cash.Also, the wide range of stocks in the sector offer investors vastly differing risk and returndynamics.U.S. health care spending is projected to climb at a faster pace than economic growth in comingyears as the population ages and President Barack Obama‘s Affordable Care Act gives millionsof Americans greater access to care.The Centers for Medicare and Medicaid Services projects that total health care spending willrise 70 percent over last year’s estimated level of $2.8 trillion to $4.8 trillion by 2021. That’salmost 20 percent of U.S. gross domestic product.“There’s just a lot more money flowing into health care and we’re seeing the markets reactaccordingly,” says Derek Taner, a portfolio manager at Invesco.President Obama‘s re-election in November gave the sector a boost by removing theuncertainty surrounding the implementation of the Affordable Care Act. Republican candidateMitt Romney had said that he would overturn the act if elected.The biggest beneficiaries of the act will likely be hospital companies, which have the potential toincrease their earnings significantly, says Taner, who manages Invesco‘s Global Health Carefund.So-called managed-care companies should also benefit from the increase in spending, thoughthey also face higher taxes and restrictions on how they can price their coverage, so the law willbe challenging to them too.HCA Holdings Inc., a bellwether for the hospital industry, has gained 25 percent so far this year.Tenet Healthcare Corp., a Dallas-based operator of acute care hospitals, has advanced 20percent. 1/4
  • Drugmakers, often regarded as defensive growth companies by analysts, are also emergingfrom the doldrums after lagging the broader index for much of the last decade.Pfizer Inc., the world’s biggest drugmaker by revenue, has returned 31 percent over the last 10years, compared with 113 percent for the S&P 500.The big pharmaceutical companies were shunned by investors as they faced challenges fromrising research costs and the economic slump in Europe, which prompted governments to try torein in health care spending.Drug companies were also hurt by what the industry dubbed the “patent cliff,” as anunprecedented number of patents expired on drugs worth billions of dollars in sales. Theexpiration of patents allows cheaper generic versions of drugs to replace blockbuster products.That hurts sales.Pfizer lost exclusivity for its cholesterol-fighting drug Lipitor in the U.S. in November 2011. In itsmost recent earnings report, Pfizer said that U.S. revenues from the drug plunged 87 percent inthe third quarter of 2012 to $192 million. The company will release its fourth-quarter earningsTuesday.The worst of the impact of patent expiration may now be over for the drugmakers, and themarket has already factored it into stock prices, says Mark Bussard, a health care analyst atfund manager T. Rowe Price.“The ‘patent cliff’ for most of the companies has now come and gone,” says Bussard, who is aphysician by training. “Some of the largest losses to generic competition are in the rear-viewmirror now.”Approvals for first-of-a-kind drugs have also been climbing as drugmakers continue to pursuean emerging business model focused on treatments for rare and hard-to-treat diseases.The Food and Drug Administration approved 39 new drugs last year, up from 30 the year beforeand the highest annual tally since 1997, when the agency also approved 39 drugs.In addition to being relatively low-risk investments, due to the steady demand for drugs, BigPharma also pays big dividends.The largest drug companies in the S&P 500 have higher dividend yields than the broader index,which yields 2.1 percent. Pfizer currently has a 3.6 percent yield and Merck & Co. yields 4percent.Biotechnology companies are possibly the most exciting companies in the sector and are alsoadvancing.Investing in this sector can be challenging, though, as the vast majority of drugs beingdeveloped don’t work out. 2/4
  • “It’s probably unwise … to try to pick the individual winner,” says Sam Isaly, the manager ofEaton Vance’s Worldwide Health Sciences Fund. “It depends on whether you’re a lotto playeror not.”While the Affordable Care Act ensures that money will flow into the industry in the near term,that spending can’t keep rising exponentially. At some point, the focus will turn to the cost ofthe reforms, particularly if the initial spending estimates are exceeded, causing reneweduncertainty for the industry.“That’s a longer-term concern that is going to come into play at some point,” says Invesco’sTaner. “Right now we’re in the honeymoon period. People aren’t thinking about that.”And if history is a guide, the cost estimates will likely prove too low.Upon passing the Medicare bill in 1965, the House Ways and Means Committee estimated totalprogram expenditures would amount to $1.3 billion in 1967. That estimate proved to be “wildlyoptimistic,” with the actual cost coming in at $4.6 billion, according to research by Citigrouphealth care analysts.To counter the rising costs, governments and employers will increasingly try to shift more of thecost to individual consumers, transforming the industry from an “employer-driven insurancemarket” to an “employee-driven consumer market,” says Eddie Yoon of Fidelity.“The companies that are the most innovative in helping drive costs down are going to be thegrowth companies of tomorrow,” says Yoon, who manages the investment firm’s Select HealthCare Portfolio.___AP Business Writers Matthew Perrone and Linda Johnson contributed.Check out the original source here.We hope that you felt the above article was of value. Please feel free to share this article.Keeping up with the Market News from worldwide is very important for investors and tradersalike. Whether it is political, economic or social modifications which could impact yourinvestments in the short, moderate or long term, it’s great to be in the understand.We intend to bring you the current news as it breaks, so you in front of the majority of investorsand traders . 3/4
  • 4/4Powered by TCPDF (www.tcpdf.org)